TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

[1]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Ohtsu,et al.  Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours , 2012, British Journal of Cancer.

[3]  F. Nakagawa,et al.  A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. , 2004, International journal of molecular medicine.

[4]  E. Van Cutsem,et al.  Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  M. Fukushima,et al.  Phase I study to determine the safety and pharmacokinetics of oral administration of TAS‐102 in patients with solid tumors , 2006, Cancer.

[6]  W. Scheithauer,et al.  XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results , 2011, British Journal of Cancer.

[7]  A. Fujioka,et al.  Abstract 1783: Trifluorothymidine incorporation into DNA strongly enforces the potential of TAS-102 and leads to remarkably prolonged survival of cancer patients , 2012 .

[8]  M. Fukushima,et al.  Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors , 2008, Investigational New Drugs.

[9]  N. Suzuki,et al.  Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. , 2000, International journal of oncology.

[10]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[11]  Y. Hirai.  Structure and activity of IL-1. , 1990 .

[12]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Sheridan.  EGFR inhibitors embrace KRAS , 2008, Nature Biotechnology.

[14]  Manish R. Patel,et al.  A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC). , 2012 .

[15]  W. Wolberg,et al.  The clinical pharmacology of 5-trifluoromethyl-2'-deoxyuridine. , 1972, Cancer research.

[16]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Dongsheng Tu,et al.  Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.

[18]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[19]  M. Fukushima,et al.  Phase I Clinical Study of Three Times a Day Oral Administration of TAS-102 in Patients with Solid Tumors , 2008, Cancer investigation.

[20]  N. Suzuki,et al.  Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. , 2000, Biochemical pharmacology.

[21]  Giampietro Gasparini,et al.  K-ras mutations and cetuximab in colorectal cancer. , 2009, The New England journal of medicine.